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Abstract Cellular signaling via epidermal growth factor
(EGF) and EGF-like ligands can determine cell fate and
behavior. Osteoblasts, which are responsible for forming
and mineralizing osteoid, express EGF receptors and alter
rates of proliferation and differentiation in response to EGF
receptor activation. Transgenic mice over-expressing the
EGF-like ligand betacellulin (BTC) exhibit increased
cortical bone deposition; however, because the transgene
is ubiquitously expressed in these mice, the identity of cells
affected by BTC and responsible for increased cortical bone
thickness remains unknown. We have therefore examined
the influence of BTC upon mesenchymal stem cell (MSC)
and pre-osteoblast differentiation and proliferation. BTC
decreases the expression of osteogenic markers in both
MSCs and pre-osteoblasts; interestingly, increases in
proliferation require hypoxia-inducible factor-alpha (HIF-
α), as an HIF antagonist prevents BTC-driven proliferation.
Both MSCs and pre-osteoblasts express EGF receptors
ErbB1, ErbB2, and ErbB3, with no change in expression
under osteogenic differentiation. These are the first data that
demonstrate an influence of BTC upon MSCs and the first
to implicate HIF-α in BTC-mediated proliferation.
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Introduction
The skeleton continually undergoes alterations in size and
shape in response to humoral, mechanical, and paracrine
stimuli. Degradation of pre-existing bone by osteoclasts and
ensuing replacement with osteoid by osteoblasts require
concerted activity in order to maintain skeletal homeostasis
and to prevent pathologic conditions such as osteoporosis
or osteopetrosis. Osteoblast number is partially governed by
the proliferation and osteogenic differentiation of mesen-
chymal stem cell (MSC) precursors; hence, stimuli that
enhance MSC number or osteogenic differentiation emerge
as ideal methods to combat bone loss resulting from
pharmacology or aging.
Epidermal growth factor (EGF) mediates diverse pro-
cesses of proliferation, differentiation, adhesion, and sur-
vival (Citri and Yarden 2006; Yarden and Sliwkowski
2001). The EGF family of ligands consists of EGF,
amphiregulin, betacellulin (BTC), epiregulin, epigen,
heparin-binding EGF-like growth factor (HB-EGF), and
transforming growth factor-alpha (TGF-α; Harris et al.
2003;X i a n2007). EGF signaling occurs through ErbB
receptor tyrosine kinases, of which ErbB1/EGF-R is bound
by all seven family members. Three members (EGF,
amphiregulin, and TGF-α) can only bind to ErbB1,
whereas BTC, epiregulin, and HB-EGF can also bind to
ErbB4 to form ErbB1/ErbB4 heterodimers. ErbB2, al-
though lacking any known cognate ligand, is the preferred
co-receptor for ErbB1, and the heterodimerization of ErbB2
and ErbB1 generates more potent signaling than ErbB1
homodimers (Qin et al. 2005; Yarden 2001; Yarden and
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DOI 10.1007/s00441-010-0929-0Sliwkowski 2001); ErbB3 is a pseudokinase and therefore
lacks any traditional catalytic kinase domain. Once bound
by EGF or EGF-like ligand, homo- or heterodimerized
ErbB receptors initiate multiple signaling pathways that
affect proliferation, survival, and differentiation and that are
mediated Ras-Raf-mitogen-activated protein kinase
(Ras-Raf-MAPK; Yarden and Sliwkowski 2001), the
phosphatidyl-inositol-3-kinase/Akt pathway (Xian 2007),
and phospholipase C-γ/protein kinase C (Yarden and
Sliwkowski 2001).
EGF and related ligands exert disparate effects upon
osteoblast differentiation and proliferation. In vitro studies
have revealed that EGF inhibits bone nodule formation
(Antosz et al. 1987) and decreases alkaline phosphatase
(ALP) activity (Nicolas et al. 1990). Similar findings have
been reported for osteoblastic cells treated with amphir-
egulin (Qin et al. 2005). Further, over-expression of ErbB1
in ROS rat osteosarcoma cells decreases the expression of
osteoblastic markers (Chien et al. 2000). Comparable
results are observed with in vivo models. EGF transgenic
mice, under the control of a β-actin promoter, demonstrate
a 20%–50% reduction in body weight (Wong et al. 2000)
and decreased cortical bone thickness compared with wild-
type controls (Chan and Wong 2000). Similar observations,
including impaired longitudinal growth and overall dispro-
portionate skeletal growth, are detected in mice transgenic
for BTC (Schneider et al. 2005). Whereas EGF suppresses
the osteoblastic phenotype, it demonstrates mitogenic
effects upon osteoblastic cells (Loza et al. 1995; Nicolas
et al. 1990; VandePol et al. 1989), as do amphiregulin and
TGF-α (Qin et al. 2005). Thus, a general theme regarding
EGF signaling in bone seems to be increased proliferation
and decreased osteogenic differentiation. Schneider et al.
(2009) have recently demonstrated that BTC transgenic
mice have enhanced cortical, but reduced trabecular, bone
thickness. To date, however, no study has examined the
influence of BTC upon osteoprogenitor proliferation or
differentiation. We report that BTC attenuates the osteo-
genic differentiation of MSC and committed pre-
osteoblastic cells, whilst simultaneously increasing their
proliferation through a mechanism involving the stabiliza-
tion of hypoxia-inducible factor (HIF). These are the first
data to demonstrate an influence of BTC upon MSC and
the first to implicate HIF in BTC-mediated proliferation.
Materials and methods
Cell culture Human MSCs (hMSCs) were purchased from
Lonza; cells were isolated from iliac crest bone biopsies
from a 19-year-old male African-American, a 20-year-old
male African-American, and an 18-year-old male Cauca-
sian with no known pathologic conditions. hMSCs (pas-
sages 2–6) were cultured in α-MEM supplemented with
10% fetal bovine serum (FBS; Invitrogen) and 1%
penicillin/streptomycin (P/S; Invitrogen) and maintained in
a humidified incubator at 37°C with 5% CO2. MC3T3-E1,
clone 14, pre-osteoblastic cells were purchased from
American Type Culture Collection and cultured in α-
MEM supplemented with 10% FBS and 1% P/S and
maintained in a humidified incubator at 37°C with 5%
CO2. Cells were sub-cultured with 0.05% trypsin/EDTA
when 80% confluent.
Osteogenic differentiation hMSCs or MC3T3-E1 cells were
seeded into 6-well plates at a density of 3000 cells/cm
2.
When 70% confluent, media was replaced with osteogenic
differentiation media consisting of 10% FBS, 1% P/S,
5m Mβ-glycerophosphate acid (VWR International) and
50 µg/ml L-ascorbic acid 2-phosphate (Waco) in α-MEM
(Invitrogen).
RNA extraction and quantitative polymerase chain reac-
tion Total RNA was collected with RNeasy Mini kit
(Qiagen) according to the manufacturer’s instructions and
including on-column digestion of genomic DNA. RNA
quality was assessed by the ratio of absorbance at 260 nm
and 280 nm. Total RNA (0.2–1 μg) was reverse-transcribed
with a Superscript First-Strand Synthesis System (Invitro-
gen). Quantitative reverse transcription with the polymerase
chain reaction (RT-PCR) was performed by using the
TaqMan Universal PCR Master Mix (Applied Biosystems)
on aMastercyclerrealplex2(Eppendorf); proprietaryprimers
and probes, whose sequences are not disclosed, were
purchased from Applied Biosystems. Amplification condi-
tions were 50°C for 2 min, 95°C for 10 min, followed by 40
cycles at 95°C for 15 s and 60°C for 30 s. Quantitative PCR
results were first normalized to ribosomal protein 13 (Rpl13)
transcript level to yield ΔCt. Results are expressed as 2ΔCt
or 2ΔΔCt, after Livak and Schmittgen (2001).
ALP activity assay Whole cell protein lysates were collect-
ed on days 3, 7, or 21 in 0.1% Triton X-100, 10 mM TRIS
pH 8, 1 mM EDTA, and protease inhibitor cocktail
(Calbiochem). Lysates (10 μl) were incubated with p-
nitrophenol phosphate (Sigma) and incubated at 37°C for
30 min. The reaction was terminated with the addition of
0.02 N NaOH, and activity was recorded by measuring
absorbance (450 nm) on a microplate reader.
Proliferation assays Cells were seeded into 60-mm dishes
at a density of 9500/cm
2 and cultured for 2 days, after
which the medium was removed and replaced with BTC
(0.5–500 ng/ml) in reduced-serum (2% FBS) medium. As a
positive control for proliferation, a subset of cells was
cultured in high-serum (20% FBS) medium in the absence
82 Cell Tissue Res (2010) 340:81–89of BTC. Cells were collected 4 days later by trypsinization
and counted by using a Countess automated cell counter
(Invitrogen). To determine the influence of HIF-α isoforms
upon BTC-mediated proliferation, cells were treated with
10–25 μM YC-1, a small molecule post-transcriptional
antagonist of HIF-1α accumulation (Chun et al. 2004).
Proliferation under these conditions was assessed as above.
Western immunoblotting Cells were briefly washed with
phosphate-buffered saline, and whole-cell protein lysates
were collected in 0.1% Triton X-100, 10 mM TRIS pH 8,
1 mM EDTA, supplemented with a protease and phospha-
tase inhibitor cocktail (Calbiochem). Samples were electro-
phoresed onto 7.5% TRIS-HCl gels (Bio-Rad), resolved
onto 0.2-μm nitrocellulose membranes, and blocked in non-
fat milk in TRIS-buffered saline supplemented with 0.1%
Tween-20. Immunoreactivity against HIF-1α (1:200; Cay-
man Chemical) or β-actin (1:1000; Abcam) was visualized
with appropriate horseradish-peroxidase-conjugated anti-
bodies (Jackson Immunoresearch) and ECL Plus Western
Blotting Detection Reagents (GE Healthcare). Densitomet-
ric analysis was performed with Adobe Photoshop.
Statistical analysis The experimental design involved re-
peated measures analysis or dose-response comparisons
with negative or positive controls. The data were assessed
for normality with the Shapiro Wilk test, and analysis of
variance was performed by using Proc GLM (SAS 9.1.2,
SAS Institute). Either Tukey’s or Dunnet’s tests were used
for post-hoc comparisons. Student’s t-test was used for pair-
wise comparisons of the least square means to examine
interaction effects. Statistical analyses and the type I error
was maintained at <0.05 for all comparisons. Data are
reported as arithmetic means ± SE or fold-change to BTC-
free controls ± SE.
Results
BTC inhibits osteogenic differentiation of mesenchymal
and pre-osteoblastic cells
We first examined the influence of BTC upon MSC
differentiation toward the osteogenic lineage. hMSCs were
cultured under osteogenic conditions and 0.5–500 ng/ml
BTC for 3, 7, 14, or 21 days. ALP activity increased with
time in culture in BTC-free controls, indicating progression
of hMSCs toward an osteoblastic phenotype (Fig. 1a). We
observed a trend for attenuation of ALP activity compared
with BTC-free controls at all time points and in all
concentrations of BTC. The difference in ALP activity
between BTC-free controls and cells under treatment were
significant on day 7 (5, 50, or 500 ng/ml) and day 21 (5 and
500 ng/ml; Fig. 1a). BTC-treated cells revealed significant
increases in ALP activity at day 21 compared with cells
treated with the same dose of BTC and collected at day 3,
indicating that BTC slowed, but did not arrest, the osteogenic
Fig. 1 Effect of BTC on osteogenesis. hMSC or MC3T3-E1, under
osteogenic conditions, were cultured in the presence of 0–500 ng/ml
BTC. a Alkaline phosphatase activity assays of hMSCs after 3, 7, 14,
or 21 days. b Quantitative polymerase chain reaction (qtPCR) analysis
of RUNX2 and COL1A1 expression in hMSCs after 7 days of BTC
treatment. c qtPCR analysis of Col1a2 expression in MC3T3-E1 cells
after 7 days of BTC treatment. Bars Means ± SE. *P<0.05 compared
with BTC-free culture within same timepoint; **P<0.01 compared
with BTC-free culture within same timepoint;
aP<0.05 compared with
BTC-free culture on day 3; n=3–5 per experiment per time point
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influence of BTC upon osteogenic differentiation, BTC at 50
or 500 ng/ml significantly attenuated transcription of the
osteogenictranscriptionfactorRUNX2andosteoblastmarker
COL1A1 relative to BTC-free cultures (Fig. 1b). Similar
trends were observed for both genes in cultures collected
after 14 and 21 days of BTC treatment, but this was without
statistical significance; after day 28, no significant effect of
BTC was deteted on RUNX2 or COL1A1 expression (data
not shown). Interestingly, the expression of osteocalcin, a
marker of mature osteoblasts, was not significantly affected
by BTC treatment (not shown). We examined the possibil-
ity that a stimulatory influence of BTC upon osteogenesis
was mediated by cells further committed to the osteoblastic
phenotype by using MC3T3-E1 pre-osteoblasts. Similar to
hMSC under osteogenic culture, Col1a2 expression was
reduced by BTC, although this did not achieve statistical
significance (Fig. 1c). Thus, these data indicated that BTC,
similar to EGF and EGF-like ligands TGF-α and amphir-
egulin, inhibited the differentiation of osteoprogenitor and
osteoblastic cells.
BTC increases MSC and pre-osteoblast proliferation
Based on the reported evidence that EGF and EGF-like
ligands amphiregulin and TGF-α increase osteoblast pro-
liferation (Loza et al. 1995; Nicolas et al. 1990; Qin et al.
2005; VandePol et al. 1989), we sought whether decreased
osteogenic differentiation in response to BTC was paral-
leled with changes in proliferation. hMSCs and MC3T3-E1
pre-osteoblasts were cultured in the presence of 0.5–
500 ng/ml BTC for 4 days. Addition of BTC at 5 ng/ml
significantly increased hMSC cell proliferation approxi-
mately 2.2-fold over spontaneous proliferation observed in
BTC-free cultures (Fig. 2a); BTC doses other than 5 ng/ml
had no significant effect on cell proliferation. Similarly,
MC3T3-E1 cultures with BTC demonstrated a significant
increase in proliferation compared with BTC-free cultures
(Fig. 2b), revealing a two-fold increase in cell number in
response to 5 ng/ml BTC. These data confirmed a
stimulatory influence of BTC upon cell proliferation and
further revealed that this process was independent of
mesenchymal or osteoblastic phenotype.
BTC induction of proliferation is mediated through HIF-α
stabilization
EGF and EGF-like ligands stimulate a host of intracellular
signaling cascades, including MAPK and Akt. An intrigu-
ing cascade involves activation of the transcription factor
HIF-α (Peng et al. 2006; Schultz et al. 2006; Tanaka et al.
2006), the genetic stabilization of which mediates increased
bone mass (Wan et al. 2008; Wang et al. 2007). Culture of
hMSC with 5 ng/ml BTC for 24 h revealed a trend for HIF-
1α accumulation compared with BTC-free controls, al-
though to a lesser degree than that observed in cells
cultured with the hypoxia mimetic, 100 μM cobalt chloride
(Fig. 3a, b). This effect was transient and was not observed
in cultures treated with BTC for 1, 2, 4, or 48 h (data not
shown), indicating a transient influence of BTC upon HIF-
1α stabilization. Because stable HIF-α is associated with
proliferation (as observed in tumorigenic culture; Gardner
and Corn 2008; Rankin and Giaccia 2008; Wouters and
Koritzinsky 2008), we investigated whether BTC-mediated
increases in osteoprogenitor proliferation were mediated via
HIF-1α stabilization. We confirmed that the HIF-α antag-
onist YC-1 (10 μM) prevented HIF-1α stabilization in
response to both hypoxia (1% O2) or hypoxia mimetics
(100 μM CoCl2; Fig. 3c). Co-culture of hMSC cells with
the HIF-α antagonist YC-1 revealed a dose-dependent
attenuation of 5 ng/ml BTC-mediated proliferation
(Fig. 3d). The inhibitory influence of the same doses of
YC-1 on HIF-1α levels was confirmed by Western
immunoblotting (data not shown). These findings indicated
Fig. 2 BTC stimulates cell proliferation. hMSCs (a) or MC3T3-E1
pre-osteoblasts (b) were cultured in the presence of 0.5–500 ng/ml
BTC for 4 days, after which time cells were trypsinized and counted.
Addition of BTC at 5 ng/ml significantly enhanced proliferation
compared with control cultures (white bar). Cell proliferation in
response to 20% serum is shown as a positive control. Because of
variation between experiments, data are presented as the fold-change
compared with BTC-free control. Bars Means ± SE. *P<0.05
compared with BTC-free culture; **P<0.001 compared with all other
cultures; n=3–6 per experiment per time point
84 Cell Tissue Res (2010) 340:81–89that the stimulatory effect of BTC upon cell proliferation
was mediated by stabilized HIF-α.
ErbB receptor expression in stem cells and pre-osteoblasts
The mRNA expression of ErbB receptor subtypes in hMSC
and MC3T3-E1 was examined by quantitative PCR. We
found that both naive (i.e., prior to further osteogenic
differentiation) MSC and pre-osteoblasts express EGFR/
ErbB1 (Fig. 4a), ErbB2 (Fig. 4b), and ErbB3 (Fig. 4c); no
transcript for ErbB4 was observed (data not shown). All
ErbB isoform receptors were expressed at higher levels in
MSC than in MC3T3-E1, suggesting that osteogenic
differentiation decreased ErbB expression, or that the levels
changed as a function of immortalization. However, hMSCs
cultured for 21 days under osteogenic or maintenance
conditions revealed no significant differences in the
transcript expression of ErbB1, ErbB2,o rErbB3 (not
shown), suggesting that the relative differences in individ-
ual ErbB isoform expression was a species, rather than
phenotypic, difference.
BTC does not influence osteoclast-regulating factors
interleukin-6, osteoprotegerin, or RANKL
A potential explanation for the site-specific effects of BTC
upon cortical and trabecular remodeling involves the
regulation of osteoclast formation by osteoblasts. Thus,
we examined the influence of BTC upon the expression of
interleukin-6 (IL-6), osteoprotegerin (OPG), and receptor
activator of NF-κB ligand (RANKL) in MSCs under
osteogenic conditions. BTC had no effect upon IL-6
expression (Fig. 5a) and elicited a trend, albeit insignificant,
for increased RANKL expression (Fig. 5b). In contrast, BTC
at 50 or 500 ng/ml significantly decreased OPG transcript
after 7 days in culture (Fig. 5c); the inhibitory influence of
BTC upon the OPG transcript was transitory and was not
observed after 14 or 21 days in culture. The significant
 Fig. 3 Influence of HIF-1α on BTC-driven proliferation. a hMSCs
were cultured in the presence of 5 ng/ml BTC or 100 μM CoCl2 for
24 h, after which time whole-cell protein lysates were analyzed for
HIF-1α, as normalized to β-actin. Treatment with BTC stabilized
HIF-1α levels compared with BTC-free controls. b Western
immunoblotting showed increased HIF-1α levels in BTC- and
CoCl2-treated cells compared with control cultures. c Western
immunoblotting demonstrated the induction of HIF-1α expression in
response to hypoxia (1% O2) or hypoxia mimetics (100 μM CoCl2),
whereas the addition of 10 μM YC-1 prevented HIF-1α stabilization
under such conditions. d hMSCs were cultured in the presence of 0–
25 μM YC-1 in the absence (white bars) or presence (black bars)o f
5 ng/ml BTC. The addition of 10 or 25 μM YC-1 attenuated BTC-
driven proliferation. Because of variation between experiments, data
are presented as fold change compared with BTC-free control. Bars
Means ± SE. *P<0.05 compared with BTC-free culture; n=3–4
experimental replicates
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RANKL expression promoted a trend for increased
RANKL/OPG ratios, thereby favoring osteoclastogenesis,
although the trend did not achieve statistical significance
(Fig. 5d).
Discussion
The debate regarding the influence of EGF and EGF-like
ligands upon osteoblast function and differentiation is
ongoing. Whereas these growth factors have been shown
to reduce osteogenic differentiation (Antosz et al. 1987;
Nicolas et al. 1990; Qin et al. 2005), a recent report by
Schneider et al. (2009) has demonstrated that BTC
transgenic mice exhibit increased endocortical bone appo-
Fig. 5 Influence of BTC upon osteoclast regulatory factors. hMSC
were cultured under osteogenic conditions in the presence of 0.5–
500 ng/ml BTC for 7–21 days, from which total RNA lysates were
examined by qtPCR analysis for (a) IL-6,( b) RANKL,( c) OPG,o r( d)
RANKL/OPG. Bars Means ± SE. *P<0.05 compared with BTC-free
culture within same timepoint. n=3–4 per experiment per time point
Fig. 4 Profile of ERBB transcript expression. Expression of ERBB1
(a), ERBB2 (b), and ERBB3 (c) isoform transcript in hMSC and
MC3T3-E1 cells. Bars Means ± SE. ***P<0.001 compared with
MC3T3-E1; n=3–4 per experiment per condition
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with decreased trabecular bone mineral density. In order to
begin to delineate the mechanisms producing these site-
specific effects of BTC, we have examined the influence of
recombinant BTC upon the osteogenic differentiation of
MSCs and committed pre-osteoblasts. We have found that
BTC attenuates differentiation toward an osteogenic pheno-
type, as demonstrated by reductions in ALP activity and
transcription of RUNX2 and COL1A1 (Fig. 1). Interestingly,
we have observed no significant influence of BTC,
regardless of dose, upon the expression of the mature
osteoblast marker osteocalcin. Thus, BTC functions similar
to EGF (Nicolas et al. 1990) and amphiregulin (Qin et al.
2005) to reduce osteogenic differentiation. Interestingly, the
ability of EGF, and presumably of BTC, to attenuate cellular
differentiation is not specific to the osteogenic phenotype, as
EGF also decreases the chondrogenic and adipogenic
differentiation of MSCs and, in doing so, reversibly
maintains their multilineage potential (Krampera et al. 2005).
We have observed a mitogenic influence of BTC upon
MSCs (Fig. 2a) and on committed pre-osteoblasts (Fig. 2b);
co-culture with a pharmacologic antagonist, YC-1, which
promotes HIF-α degradation and inhibits its de novo
synthesis (Chun et al. 2004), dose-dependently attenuates
the proliferative response of MSCs to BTC (Fig. 3d). HIF-α
is a transcription factor that, under conditions of sufficient
molecular oxygen (i.e., under normoxia), is targeted for
proteasomal degradation; in contrast, under conditions of
reduced molecular oxygen (hypoxia), HIF-α is stabilized,
complexes with HIF-β, and translocates to the nucleus to
induce gene expression. We have recently demonstrated
that HIF-1α is responsible for increases in EP1 prostanoid
receptor under hypoxia (Genetos et al. 2009). Surprisingly,
growth factors, similar to EGF and BTC, and hormones are
able to stabilize HIF-α under non-hypoxic conditions. Fetal
calf serum, thrombin, and angiotensin II all stabilize HIF-
1α and promote its binding to DNA to induce gene
transcription in vascular smooth muscle cells (Richard et
al. 2000). Similarly, Schultz et al. (2006) have demonstrat-
ed that HIF-1α contributes to the proliferative response of
smooth muscle cells to fibroblast growth factor-2 and
platelet-derived growth factor. Hypoxia exerts pleiotropic
effects upon MSCs and has been implicated in the
commitment toward chondrogenic (Kanichai et al. 2008)
or neuronal (Pacary et al. 2006, 2007, 2008) lineages; in
contrast, we have recently shown that hypoxia attenuates
the osteogenic differentiation of MSCs (Raheja et al. 2009).
Taken together, these data indicate that growth factor
stabilization of HIF-α under nonhypoxic conditions pro-
motes cell proliferation.
EGF and EGF-like ligands also influence skeletal
remodeling by controlling bone resorption. Rats adminis-
tered high doses of EGF reveal increased osteoclast number
on trabecular bone surfaces (Marie et al. 1990), and EGF
transgenic mice produce thinner bones than wild-type
controls (Chan and Wong 2000; Xian 2007). Interestingly,
considerable controversy exists as to whether osteoclasts
express receptors for EGF or EGF-like ligands. Martineau-
Doize et al. (1988) have demonstrated that osteoclasts fail
to bind [
125I]-iodo-EGF, suggesting that osteoclasts lack
EGF receptors; these findings have subsequently been
confirmed by Zhu et al. (2007). In contrast, Yi et al.
(2008) report that EGF-receptor increases during osteoclas-
togenesis in response to RANKL, and that EGF-receptor
signaling is required for RANKL-mediated osteoclasto-
genesis. The most likely cell type influenced by EGF to
affect osteoclasts or their precursors is the osteoblast,
primarily because of the close microenvironment in which
these cells act as neighbors and modulate osteoclast
formation and activity. Osteoblasts regulate osteoclast
formation via RANKL, OPG, and IL-6, among other
cytokines. Zhu et al. (2007) have demonstrated that EGF
indirectly stimulates osteoclast formation via the decreased
OPG expression by osteoblasts; similarly, we have ob-
served a transient inhibitory influence of BTC upon OPG
expression, but no influence upon RANKL transcription.
Consequently, the ratio of the RANKL/OPG transcript
demonstrates a trend above unity, indicating a stimulatory
effect upon osteoclastogenesis.
EGF ligand binding induces manifold cellular responses
depending upon the ErbB receptors mobilized. We have
found that both MSCs and committed pre-osteoblasts
express three of the four EGF receptors, lacking any
expression of ErbB4. Among the three ErbB isoforms
found within these cells, ErbB2 is maximally expressed,
followed by ErbB1; ErbB3 is also expressed, albeit at
approximately 25-fold lower levels than ErbB2 (Fig. 4a, c).
Osteogenic differentiation has revealed no significant
change in ErbB isoform expression (Fig. 4a–c). Based
upon a Scatchard analysis revealing the KD of ErbB1 and
BTC as 0.5 nM (4.5 ng/ml) in 3T3 cells (Watanabe et al.
1994), our chosen doses of 0.5, 5, 50, and 500 ng/ml
correspond to, approximately, 10%, 50%, 90%, and 99%
ErbB1 receptor occupancy, respectively. The lack of
expression of ErbB4, a binding partner for BTC, in MSC
or pre-osteoblasts indicates that the stimulatory influence of
BTC upon proliferation and its inhibitory effect upon
differentiation is mediated by ErbB1 homodimers or
ErbB1/ErbB2 heterodimer or, potentially, an ErbB2/ErbB3
heterodimer (Pinkas-Kramarski et al. 1998). Indeed, each of
these processes (increased proliferation and attenuated
differentiation) are probably regulated by a different ErbB
receptor complex, because of the variable affinity of ErbB1
and ErbB2 for ligands.
Our findings do not however reveal the mechanisms that
explain site-specific differences in cortical formation and
Cell Tissue Res (2010) 340:81–89 87trabecular resorption in BTC transgenic mice. The most
likely scenario results from the different microenvironments
in which osteoblasts reside in cortical versus trabecular bone:
osteoblasts within a remodeling compartment in cancellous
bone are intimately exposed to a cytokine-rich red-marrow
milieu,whereasosteoblastswithincorticalbonearecontrolled
more by mechanical or systemic factors such as parathyroid
hormone (PTH) and1α,25-(OH)2 vitamin D3 (Mundy 1999).
Indeed, vitamin D3 has been shown to enhance osteoblast
maturation in response to EGF (Yarram et al. 2004), and
PTH induces EGF and EGF-like ligand expression (Qin and
Partridge 2005; Qin et al. 2005; Swarthout et al. 2001; Xian
2007). In contrast, localized factors present within the bone
marrow stroma, such as insulin-like growth factor (IGF),
decrease osteoblast differentiation and instead promote
proliferation (VandePol et al. 1989). IGF is a powerful
regulator of post-natal bone growth, and EGF regulates IGF
and IGF-binding protein (IGFBP) levels (Xian 2007). In
further support of this possibility, reductions in body weight
that occur in EGF transgenic mice are associated with serum
IGFBP-3 levels (Chan and Wong 2000). Thus, an unexam-
ined scenario is whether the stunted growth observed in EGF
and BTC transgenics is indirectly mediated through altered
IGF bioavailability.
This study has revealed that BTC stimulates the
proliferation and inhibits the osteogenic differentiation of
both MSCs and committed pre-osteoblasts. This stimulato-
ry influence of BTC upon mesenchymal proliferation is
mediated via the stabilization of HIF-1α. We have found
that MSCs and committed osteoprogenitors express ErbB1,
ErbB2, and ErbB3 but fail to express ErbB4; we have
observed no change in the expression of these receptors
under osteogenic conditions. Whereas previous work has
demonstrated the influence of EGF, TGF-α, and amphir-
egulin upon osteoblast proliferation, our data are the first to
reveal a similar role for BTC and are the first to provide a
mechanistic explanation involving HIF-1α.
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